The role of multimodal salvage therapy in the management of recurrent adrenocortical carcinoma

Toshiki Kijima, Shohei Fukuda, Hiroshi Fukushima, Sho Uehara, Yosuke Yasuda, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Kazutaka Saito, Yasuhisa Fujii

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Adrenocortical carcinoma is an aggressive tumor which often recurs despite apparent complete resection. This study assessed the long-term outcomes for patients with recurrent adrenocortical carcinoma after multimodal salvage therapy with chemotherapy, chemoradiotherapy and surgery. Methods: We retrospectively reviewed medical records of patients who had a pathological diagnosis of adrenocortical carcinoma between 1996 and 2017. Kaplan–Meier curves were used to assess progression-free and cancer-specific survivals among all patients and cancer-specific survival among patients with tumor recurrence. Log-rank test was used to compare patient survivals by modality of salvage therapy (chemotherapy, chemoradiotherapy and chemotherapy/chemoradiotherapy plus surgery). Results: Of 20 patients who underwent initial surgery, recurrence occurred in 14 (70%) with a median interval of 7.5 (range 1.0–12.6) months. Salvage therapy provided was chemotherapy only (n = 7), chemoradiotherapy (n = 2) and chemotherapy/chemoradiotherapy plus surgery (n = 5). Of the five patients who received salvage surgery, three underwent repeated resections. The potential benefit of multimodal salvage therapy was suggested in five patients (4 with chemotherapy/chemoradiotherapy plus surgery and 1 with chemoradiotherapy) who achieved durable disease control (cancer-specific survival from initial recurrence, 22–258 months). With a median follow-up of 25 months from recurrence, the 5-year cancer-specific survival rate was 58%. cancer-specific survival after recurrence was prolonged in patients with ≤ stage 3 disease, positive response to chemotherapy/chemoradiotherapy and salvage surgery. Conclusions: Long-term disease control and survival could be achieved in highly selected patients with recurrent adrenocortical carcinoma using a multidisciplinary approach. Patients who had relatively limited recurrent sites and responded well to chemotherapy/chemoradiotherapy may be considered for salvage surgery on a case-by-case basis.

Original languageEnglish
Pages (from-to)436-442
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume53
Issue number5
DOIs
StatePublished - 1 May 2023
Externally publishedYes

Keywords

  • chemotherapy
  • multimodal therapy
  • radiotherapy
  • recurrent adrenocortical carcinoma
  • salvage surgery

Fingerprint

Dive into the research topics of 'The role of multimodal salvage therapy in the management of recurrent adrenocortical carcinoma'. Together they form a unique fingerprint.

Cite this